Online inquiry

IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10515MR)

This product GTTS-WQ10515MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10515MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1313MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ14960MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
GTTS-WQ1990MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ2316MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ7345MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ9929MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-004
GTTS-WQ14359MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ12160MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW